Hyaluronic Acid, Amino Acids and Skin Quality.
Interest in skin quality has changed considerably over the past few years.
For a long time, injectable treatments in cosmetic medicine were discussed predominantly in terms of relaxing muscles or replacing facial volume. There is now considerably more interest in the biology of the skin itself: hydration, extracellular matrix organisation, fibroblast function and the changes that occur within the dermis as we age.
One area of research has examined formulations that combine hyaluronic acid with selected amino acids.
The scientific rationale is interesting, particularly when we look at what happens to fibroblasts and the extracellular matrix in laboratory studies. The human clinical evidence is less developed, which is an important distinction when interpreting claims about collagen, elastin and skin rejuvenation.
The extracellular matrix matters
The dermis is more than a layer of collagen beneath the surface of the skin. Its extracellular matrix is a complex biological environment containing collagen, elastin, fibronectin, hyaluronic acid and numerous other proteins and molecules. Fibroblasts live within this environment and contribute to producing, organising and remodelling many of its components.
As skin ages, this system changes. Collagen becomes increasingly fragmented and disorganised. Elastic fibres undergo structural changes. Hyaluronic acid distribution and water-binding characteristics alter, while communication between fibroblasts and their surrounding matrix becomes less effective.
Sun exposure adds another layer to this process. Chronic ultraviolet exposure influences collagen breakdown, cellular signalling, pigmentation and many of the structural changes we associate with photoageing.
This is one reason I find the extracellular matrix more useful to think about than collagen alone. Skin ageing involves a biological system rather than the decline of a single protein.
Where does hyaluronic acid fit?
Hyaluronic acid is naturally present within the extracellular matrix and has a considerable capacity to interact with water. Most people encounter the term in skincare or in discussions about dermal fillers, but those uses should not all be regarded as equivalent. Hyaluronic acid can differ substantially in molecular weight, concentration, chemical modification and physical behaviour.
A highly structured hyaluronic acid gel designed to create volume has very different physical properties from a more fluid, non-cross-linked preparation. Hyaluronic acid also interacts with cells and the surrounding extracellular environment. Its biological behaviour can vary according to factors including molecular size and formulation.
This has led researchers to investigate whether combining hyaluronic acid with other components of normal cellular metabolism might influence fibroblast activity. Amino acids are one such area of investigation.
Why amino acids?
Amino acids are the building blocks from which proteins are made. Collagen is particularly rich in glycine and proline, while other amino acids contribute to collagen synthesis and to proteins elsewhere within the extracellular matrix. Elastin also has a characteristic amino-acid composition.
Simply supplying amino acids does not mean that a fibroblast will automatically produce new collagen or elastin. Cellular protein synthesis is highly regulated.
Can particular combinations and concentrations of amino acids alter fibroblast behaviour and extracellular-matrix production? There is evidence that they can, under experimental conditions.
What has been found in fibroblasts?
A 2018 laboratory study investigated different combinations of amino acids and hyaluronic acid using cultured human dermal fibroblasts.
The researchers examined expression of genes involved in the extracellular matrix and also measured selected proteins. Different amino-acid combinations did not produce identical responses. The proportions of individual amino acids appeared to influence the expression and production of collagen- and elastin-related components.
This is useful mechanistic evidence, but there are obvious limitations.
The experiment involved cultured cells rather than intact human skin. The primary fibroblasts were derived from a single donor. Cells growing under controlled laboratory conditions also lack much of the biological complexity present in living tissue.
The study therefore tells us something about what these cells are capable of doing when exposed to particular formulations. It can’t tell us how much visible change a person will experience following treatment.
A subsequent study published in 2022 examined a defined mixture of six amino acids: glycine, alanine, proline, valine, leucine and lysine.
In cultured human skin fibroblasts, the mixture increased expression of genes associated with elastin, fibronectin and type I collagen. The investigators also found evidence suggesting involvement of the mTOR signalling pathway, which plays an important role in regulating cellular growth and protein synthesis.
Gene expression is not the same as new collagen in human skin
The language used around skin treatments often moves very quickly from laboratory observations to statements such as “stimulates collagen”.
Biologically, several steps have been compressed into those two words.
A cell may increase transcription of a collagen-related gene. That messenger RNA then needs to be translated into protein. Collagen precursors undergo further processing, secretion, assembly and cross-linking before becoming part of an organised extracellular matrix. The resulting tissue then needs to change sufficiently to produce a clinically meaningful effect.
These are related processes, but they are not interchangeable.
An increase in COL1A1 gene expression, for example, is evidence that a pathway involved in type I collagen production has been altered. It is not, by itself, evidence that a clinically significant quantity of organised new collagen has subsequently appeared in a patient's dermis.
Some laboratory studies have gone beyond gene expression and examined extracellular-matrix proteins, which strengthens the mechanistic evidence. Translating those findings into claims about human skin still requires futher clinical studies.
Elastin deserves similar caution
Elastin is another important component of the dermal extracellular matrix. Elastic fibres allow skin and other tissues to deform and then return towards their previous shape. Their biology is complex: mature elastic fibres contain elastin together with an organised microfibrillar architecture.
The laboratory studies described above have identified changes involving elastin-related gene expression, and earlier work also investigated elastin protein production.
Those findings need further investigation.
They do not mean that an increase in laboratory elastin markers can automatically be translated into clinically “tighter” or more elastic skin.
And what about fibronectin?
Fibronectin receives far less attention than collagen, although biologically it is extremely interesting. It is an extracellular-matrix glycoprotein involved in cell adhesion, migration, matrix organisation and communication between cells and their surrounding environment.
The 2022 fibroblast study reported increased expression of fibronectin-related genes following exposure to the six-amino-acid mixture.
FN1 gene expression, fibronectin protein synthesis, deposition of fibronectin into an organised extracellular matrix and a clinically detectable change in human skin are progressively different levels of evidence.
Treating them as though they demonstrate the same thing can make mechanistic research sound considerably more definitive than it actually is.
Does laboratory biology translate into human skin?
This is the big question, right?
There is some human research examining injectable preparations containing hyaluronic acid and amino acids, although the clinical literature remains relatively small.
A histological study published in 2021 examined people treated with a hyaluronic-acid and amino-acid preparation. Biopsies taken before treatment and three months afterwards were assessed histologically. The researchers reported changes including increased fibroblast activity, type III reticular collagen, vascularity and epidermal thickness.
Histology is valuable because it moves beyond surface photography and subjective assessments. At the same time, findings from an individual study need to be interpreted within its methodology, sample size and the particular formulation and treatment protocol being investigated.
Another study examined the periorbital area after a series of injections containing hyaluronic acid and amino acids. Twenty-three women completed the study. Changes were reported in wrinkle and dark-circle assessment measures after treatment.
There was no untreated comparison group, the study was relatively small and follow-up was short.
These limitations are important because facial appearance can be influenced by photography, hydration, lighting, measurement technique and natural variability.
What can we reasonably conclude?
The evidence currently operates at several different levels.
At a mechanistic level, selected combinations of amino acids can alter the behaviour of cultured human fibroblasts. Changes have been demonstrated in pathways involving collagen, elastin and fibronectin. Some experimental work has also assessed protein production rather than gene expression alone.
At a tissue level, limited human histological research suggests that injectable hyaluronic-acid and amino-acid preparations may produce measurable biological changes within treated skin.
At a clinical level, small studies have reported changes in aspects of skin appearance following treatment, although the evidence base remains limited by study size, study design and relatively short follow-up.
These findings are scientifically interesting, but larger controlled studies would give us much greater confidence about the magnitude of any clinical effect, which patients are most likely to benefit, how long changes persist and whether different formulations produce meaningfully different outcomes.
Skin quality also needs to be assessed in context
A patient may describe their concern as poor skin quality when several different anatomical processes are contributing to what they see. Fine surface wrinkling, photodamage and changes within the dermis are different from facial volume loss. Pigmentation requires its own assessment. Dynamic lines relate to muscle activity. Under-eye concerns can arise from combinations of skin translucency, pigmentation, vascular visibility, hollowing, fat prolapse and changes in the supporting anatomy.
The treatment that makes sense depends on what is actually producing the concern.
This is particularly relevant when considering treatments intended primarily to influence the skin. Biological activity within the dermis cannot be expected to correct every structural feature associated with facial ageing.
Injectable treatments still involve risk
Discussion of skin biology can make these procedures sound deceptively simple. Any procedure involving repeated penetration of the skin can produce pain, swelling, redness, bruising and infection. Injectable procedures can have additional complications related to the material injected, anatomical location and injection technique. Rare vascular complications can be serious. Suitability therefore depends on more than whether somebody would like their skin to look different. Medical history, medications, previous procedures, active skin disease, anatomy, the nature of the concern and realistic expectations all form part of a proper clinical assessment.
How I interpret the research
What interests me most about this field is the broader biology of skin rather than the familiar shorthand of “stimulating collagen”. The research is starting to show how fibroblasts respond to their biochemical environment and how several components of the extracellular matrix may be influenced at the same time.
Collagen is only one part of that system. Elastin, fibronectin, hyaluronic acid, cellular signalling and the organisation of the surrounding matrix all contribute to how skin behaves and changes over time.
At present, the laboratory evidence is more developed than the long-term clinical evidence. We have a reasonable mechanistic basis for understanding how these formulations may affect fibroblast activity, alongside early human studies suggesting measurable changes in treated skin. What remains less certain is the magnitude of those changes, how consistently they occur between patients and for how long they persist.
That is where the next generation of research becomes important. Larger controlled studies, objective tissue measurements and longer follow-up will help determine whether the biological effects observed in the laboratory translate into clinically meaningful and durable improvements in skin quality.